These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3978647)

  • 21. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of 13-cis-retinoic acid in humans.
    Kerr IG; Lippman ME; Jenkins J; Myers CE
    Cancer Res; 1982 May; 42(5):2069-73. PubMed ID: 7039821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative and reductive metabolism of 9-cis-retinoic acid in the rat. Identification of 13,14-dihydro-9-cis-retinoic acid and its taurine conjugate.
    Shirley MA; Bennani YL; Boehm MF; Breau AP; Pathirana C; Ulm EH
    Drug Metab Dispos; 1996 Mar; 24(3):293-302. PubMed ID: 8820419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
    Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
    Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
    Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
    Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
    Raymond E; Alexandre J; Faivre S; Vera K; Materman E; Boni J; Leister C; Korth-Bradley J; Hanauske A; Armand JP
    J Clin Oncol; 2004 Jun; 22(12):2336-47. PubMed ID: 15136596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of 13-cis-, all-trans-, 13-cis-4-oxo-, and all-trans-4-oxo retinoic acid after intravenous administration in the cynomolgus monkey.
    Sandberg JA; Eckhoff C; Nau H; Slikker W
    Drug Metab Dispos; 1994; 22(1):154-60. PubMed ID: 8149876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
    Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
    Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
    Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
    Lee JS; Newman RA; Lippman SM; Huber MH; Minor T; Raber MN; Krakoff IH; Hong WK
    J Clin Oncol; 1993 May; 11(5):959-66. PubMed ID: 8487058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of acne rosacea with 13-cis-retinoic acid].
    Lembo G; Giannetti A
    Med Cutan Ibero Lat Am; 1987; 15(4):274-6. PubMed ID: 2961964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of 9-cis retinoic acid in adults with solid tumors.
    Kurie JM; Lee JS; Griffin T; Lippman SM; Drum P; Thomas MP; Weber C; Bader M; Massimini G; Hong WK
    Clin Cancer Res; 1996 Feb; 2(2):287-93. PubMed ID: 9816171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid.
    Bollag W; Ott F
    Dermatology; 1999; 199(4):308-12. PubMed ID: 10640839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer.
    Cassidy J; Lippman M; Lacroix A; Peck G
    Eur J Cancer Clin Oncol; 1982 Oct; 18(10):925-8. PubMed ID: 6962067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Boost for retinoic acid cancer therapy.
    Habeck M
    Drug Discov Today; 2002 Oct; 7(20):1024-5. PubMed ID: 12546884
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice.
    Mbatia HW; Ramalingam S; Ramamurthy VP; Martin MS; Kwegyir-Afful AK; Njar VC
    J Med Chem; 2015 Feb; 58(4):1900-14. PubMed ID: 25634130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinol (vitamin A) is a cofactor in CD3-induced human T-lymphocyte activation.
    Allende LM; Corell A; Madroño A; Góngora R; Rodríguez-Gallego C; López-Goyanes A; Rosal M; Arnaiz-Villena A
    Immunology; 1997 Mar; 90(3):388-96. PubMed ID: 9155646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.